FDA committee expected to look at ADHD drugs

An FDA advisory committee meets next week to examine how best to study the risks presented by drugs for attention deficit hyperactivity disorder while still allowing physicians to prescribe them. One of the drugs expected to be scrutinized is Shire's Adderall, which was associated with 20 deaths but is on the market in Canada and the U.S. A Shire representative says the company will have representatives at the meeting but they are not scheduled to speak.

View Full Article in:

Newsday (Long Island, N.Y.) (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX